Predict your next investment

Corporation
HEALTHCARE | Medical Equipment & Supplies
archimed.co.uk

See what CB Insights has to offer

Stage

Acquired | Acquired

About Archimed

Archimed has developed two easy-to-use wound dressings that can help accelerate wound healing. The company's products, Oxyzyme and Iodozyme, were developed in the UK by a scientific team with a long history of medical innovation. Professor Paul Davis, Archimed's CTO, patented the technology which enabled the development of the highly successful Clear-Blue pregnancy test.

Archimed Headquarter Location

King Edward Court, King Edward Road Knutsford

Cheshire, England, WA16 0BE,

United Kingdom

+44 (0) 1565 654920

Latest Archimed News

ArchiMed arranges refinancing for NAMSA

Oct 8, 2021

ArchiMed has arranged the refinancing for Toledo, Ohio-based NAMSA, a contract research organization.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Archimed Patents

Archimed has filed 2 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/4/2004

4/19/2011

Traumatology, Medical treatments, Epidermal nevi, neoplasms, cysts, Injuries, Medical equipment

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

6/4/2004

00/00/0000

Grant Date

4/19/2011

00/00/0000

Title

Subscribe to see more

Related Topics

Traumatology, Medical treatments, Epidermal nevi, neoplasms, cysts, Injuries, Medical equipment

Subscribe to see more

Status

Grant

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.